Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs VRCA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–1 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: DMAC 3 – 2 VRCA (1 Tie) Matrix Metrics: DMAC 7 – 1 VRCA

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Verrica Pharmaceuticals Inc. (VRCA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas VRCA carries 31.3/100 (SELL) at $3.37 (N/M Forward P/E, -87.2% operating margin).

  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile VRCA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs VRCA
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
VRCA NASDAQ
Verrica Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$3.37
-5.48% 1D
Market Cap $63.9M
TTM Revenue $30M
Forward P/E N/M
Beta / 30D Vol 1.93β · 92% Vol
Unified Composite Score
31.3 / 100 SELL
Tech 20.0 Fund 38.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.8%), weak momentum, RSI 45
RSI-14: 44.5 · SMA20: $3.48 · SMA50: $4.02

6-Pillar Scorecard Institutional Category Breakdown (DMAC 3 – 2 VRCA)

Columns: Metric · DMAC · VRCA
1. Valuation Multiples VRCA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.5x
2. Growth & Scale DMAC
Revenue Growth (YoY) +0.0% -53.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $30M
Market Cap $503.1M $63.9M
3. Profitability & Quality DMAC
Gross Margin N/A 37.7%
Operating Margin 0.0% -87.2%
Net Profit Margin 0.0% -102.8%
Return on Equity (ROE) -114.6% -240.4%
4. Balance Sheet & Cash Flow VRCA
Cash Generation (TTM) -$32M -$14M
Cash Flow Margin N/A -46.5%
Net Cash / Leverage $4.9M Net Cash $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 106.3% (14th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (7) vs VRCA (1)
Institutional Metric DMAC VRCA Criterion Row Edge
Market Capitalization
Scale
$503.1M $63.9M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -53.9% Higher Growth DMAC
Operating Margin (TTM)
Profitability
0.0% -87.2% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -102.8% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -240.4% Higher ROE DMAC
52-Week Range Position
Momentum
55% ($5–$11) 4% ($3–$10) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 1.93β · 92% Vol Lower Realized Risk VRCA
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 31.3 / 100 (SELL) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
N/A $30M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 37.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$14M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +17.56 pp
DMAC: +11.16% · VRCA: -6.4%
3M Horizon DMAC +55.41 pp
DMAC: +27.31% · VRCA: -28.1%
6M Horizon DMAC +90.82 pp
DMAC: +48.15% · VRCA: -42.67%
1Y Horizon DMAC +68.31 pp
DMAC: +55.26% · VRCA: -13.05%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue VRCA Revenue DMAC Op. Margin VRCA Op. Margin Margin Leader
FY2018 $0M N/A -1352.2% N/A DMAC
FY2021 N/A $10M N/A -257.6% VRCA
FY2022 N/A $10M N/A -235.8% VRCA
FY2023 N/A $10M N/A -1283.4% VRCA
FY2024 N/A $10M N/A -871.3% VRCA
FY2025 N/A $40M N/A -34.2% VRCA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRCA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRCA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRCA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $63.9M market capitalization and -87.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs VRCA Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Verrica Pharmaceuticals Inc. (VRCA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas VRCA carries 31.3/100 (SELL) at $3.37 (N/M Forward P/E, -87.2% operating margin). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile VRCA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VRCA at -53.9% YoY revenue growth and +0.0% YoY earnings growth on $30M TTM revenue (37.7% gross margin, -87.2% operating margin). Across the 6-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while VRCA shifted +300.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRCA.

VRCA screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VRCA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-46.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus VRCA (-240.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, VRCA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.93β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.